AU2024267020A1 — Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
Assigned to Karuna Therapeutics Inc · Expires 2025-01-02 · 1y expired
What this patent protects
Oral compositions comprising pluralities of xanomeline beads and trospium beads that are also used in methods of treating a disease and disorder that includes schizophrenia, Alzheimer's disease, Parkinson's disease, depression, movement disorders, drug addiction, tauopathy, and…
USPTO Abstract
Oral compositions comprising pluralities of xanomeline beads and trospium beads that are also used in methods of treating a disease and disorder that includes schizophrenia, Alzheimer's disease, Parkinson's disease, depression, movement disorders, drug addiction, tauopathy, and synucleinopathy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.